Search Results - "гиперэозинофилия"

Relation: https://journal.pulmonology.ru/pulm/article/view/4118/3547; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1468; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1469; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1491; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1492; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1493; Nguyen Y., Guillevin L. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Semin. Respir. Crit. Care Med. 2018; 39 (4): 471-481. DOI:10.1055/s-0038-1669454.; Probst M., Slevogt H. Eosinophile granulomatose mit polyangiitis. Pneumologie. 2022; 76 (1): 15-16. DOI:10.1055/a-1538-9531.; Furuta S., Iwamoto T., Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol. Int. 2019; 68 (4): 430-436. DOI:10.1016/j.alit.2019.06.004.; Navarro-Mendoza E.P., Tobdn G.J. Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr. Rheumatol. Rep. 2018; 20 (5): 23. DOI:10.1007/s11926-018-0736-2.; Wechsler M.E., Akuthota P., Jayne D. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 2017; 376 (20): 1921-1932. DOI:10.1056/NEJMoa1702079.; Comarmond C., Pagnoux C., Khellaf M. et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013; 65 (1): 270-281. DOI:10.1002/art.37721.; Hellmich B., Csernok E., Gross W.L. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann. N. Y. Acad. Sci. 2005; 1051: 121-131. DOI:10.1196/annals.1361.053.; Marvisi C., Sinico R.A., Salvarani C. et al. New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. Intern. Emerg. Med. 2019; 14 (8): 1193-1197. DOI:10.1007/s11739-019-02166-5.; Bayrak Durmaz M.S., Qelebi Sozener Z., Bavbek S. Eosinophilic granulomatosis with polyangitis: a new target for biologicals. Tuberk. Toraks. 2022; 70 (1): 93-101. DOI:10.5578/tt.20229911.; Khoury P., Grayson P.C., Klion A.D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 2014; 10 (8): 474-483. DOI:10.1038/nrrheum.2014.98.; Анаев Э.Х., Чучалин А.Г. Легочные эозинофилии: диагностика, подходы к терапии. Пульмонология. 2012; (4): 106-115. DOI:10.18093/0869-0189-2012-0-4-106-115.; Yasir M., Goyal A., Bansal P., Sonthalia S. Corticosteroid adverse effects. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531462/ [Accessed July 30, 2022].; Masi A.T., Hunder G.G., Lie J.T. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33 (8): 1094-1100. DOI:10.1002/art.1780330806.; Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am. J. Med. 2003; 115 (4): 284-290. DOI:10.1016/s0002-9343(03)00359-0.; Yilmaz І., Tutar N., Sim§ek Z.O. et al. Clinical and serological features of eosinophilic and vasculitic phases of eosinophilic granulomatosis with poliangiitis: a case series of 15 patients. Turk. Thorac. J. 2017; 18 (3): 72-77. DOI:10.5152/TurkThoracJ.2017.16040.; Sinico R.A., Di Toma L., Maggiore U. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005; 52 (9): 2926-2935. DOI:10.1002/art.21250.; Nanzer A.M., Wechsler M.E. Eosinophilic granulomatosis with polyangiitis. In: Jackson D.J., Wechsler M.E., eds. Eosinophilic lung diseases. [ERS monograph]. Sheffield: European Respiratory Society; 2022: 177-192. DOI:10.1183/2312508X.10029820.; Cottin V., Khouatra C., Dubost R. et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy. 2009; 64 (4): 589-595. DOI:10.1111/j.1398-9995.2008.01854.x.; Kataoka H., Tomita T., Kondo M., Masaya Mukai M. Presence of purpura is related to active inflammation in association with IL-5 in eosinophilic granulomatosis with polyangiitis. Rheumatol. Int. 2021; 41 (2): 449-454. DOI:10.1007/s00296-020-04672-8.; Geetha D., Jefferson J.A. ANCA-associated vasculitis: core curriculum 2020. Am. J. Kidney Dis. 2020; 75 (1): 124-137. DOI:10.1053/j.ajkd.2019.04.031.; Sinico R.A., Bottero P. Churg-Strauss angiitis. Best Pract. Res. Clin. Rheumatol. 2009; 23 (3): 355-366. DOI:10.1016/j.berh.2009.02.004.; Wechsler M.E. Pulmonary eosinophilic syndromes. Immunol. Allergy Clin. North Am. 2007; 27 (3): 477-492. DOI:10.1016/j.iac.2007.07.005.; Gioffredi A., Maritati F., Oliva E., Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front. Immunol. 2014; 5: 549. DOI:10.3389/fimmu.2014.00549.; Vaglio A., Strehl J.D., Manger B. et al. IgG4 immune response in Churg-Strauss syndrome. Ann. Rheum. Dis. 2012; 71 (3): 390-393. DOI:10.1136/ard.2011.155382.; Dejaco C., Oppl B., Monach P. et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One. 2015; 10 (3): e0121737. DOI:10.1371/journal.pone.0121737.; Dallos T., Heiland G.R., Strehl J. et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 2010; 62 (11): 3496-3503. DOI:10.1002/art.27678.; Vaglio A., Zwerina J. IgG4-related disease. N. Engl. J. Med. 2012; 366 (17): 1643-1647. DOI:10.1056/NEJMc1202768.; Vaglio A., Casazza I., Grasselli C. et al. Churg-Strauss syndrome. Kidney Int. 2009; 76 (9): 1006-1011. DOI:10.1038/ki.2009.210.; Schleimer R.P., Bochner B.S. The effects of glucocorticoids on human eosinophils. J. Allergy Clin. Immunol. 1994; 94 (6, Pt 2): 12021213. DOI:10.1016/0091-6749(94)90333-6.; Новиков П.И., Зыкова А.С., Моисеев С.В. Современная терапия системных васкулитов: достижения и перспективы. Терапевтический архив. 2018; 90 (1): 76-85. DOI:10.17116/terarkh201890176-85.; Kahn J.E., Grandpeix-Guyodo C., Marroun I. et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J. Allergy Clin. Immunol. 2010; 125 (1): 267-270. DOI:10.1016/j.jaci.2009.10.014.; Yates M., Watts R.A., Bajema I.M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016; 75 (9): 1583-1594. DOI:10.1136/annrheum-dis-2016-209133.; Ribi C., Cohen P., Pagnoux C. et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized open-label study of seventy-two patients. Arthritis Rheum. 2008; 58 (2): 586-594. DOI:10.1002/art.23198.; Guillevin L., Pagnoux C., Seror R. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculit-ides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011; 90 (1): 19-27. DOI:10.1097/MD.0b013e-318205a4c6; Cohen P., Pagnoux C., Mahr A. et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007; 57 (4): 686-693. DOI:10.1002/art.22679.; Saku A., Furuta S., Hiraguri M. et al. Long-term outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 2018; 45 (8): 1159-1166. DOI:10.3899/jrheum.171352.; Tsurikisawa N., Taniguchi M., Saito H. et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann. Allergy Asthma Immunol. 2004; 92 (1): 80-87. DOI:10.1016/S1081-1206(10)61714-0.; Puechal X., Pagnoux C., Baron G. et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis or polyarteritis nodosa without poor prognosis factors: a random-ized-controlled trial. Arthritis Rheumatol. 2017; 69 (11): 2175-2186. DOI:10.1002/art.40205.; Tsukadaira A., Okubo Y., Kitano K. et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc. 1999; 20 (1): 39-44. DOI:10.2500/108854199778681486.; Fagni F., Bello F., Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front. Med. (Lausanne). 2021; 8: 627776. DOI:10.3389/fmed.2021.627776.; Rosenberg H.F., Phipps S., Foster P.S. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 2007; 119 (6): 1303-1310. DOI:10.1016/j.jaci.2007.03.048.; Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651-659. DOI:10.1016/S0140-6736(12)60988-X.; Rothenberg M.E., Klion A.D., Roufosse F.E. et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med 2008; 358 (12): 1215-1228. DOI:10.1056/NEJ-Moa070812.; Stein M.L., Collins M.H., Villanueva J.M. et al. Anti-IL-5 (mepoli-zumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 2006; 118 (6): 1312-1319. DOI:10.1016/j.jaci.2006.09.007.; Steinfeld J., Bradford E.S., Brown J. et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. 2019; 143 (6): 2170-2177. DOI:10.1016/j.jaci.2018.11.041.; Jachiet M., Samson M., Cottin V. et al. Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 2016; 68 (9): 2274-2282. DOI:10.1002/art.39663.; Wechsler M.E., Hickey L., Garin M. et al. Efficacy of reslizumab treatment in exacerbation-prone patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. Pract. 2020; 8 (10): 3434-3442. DOI:10.1016/j.jaip.2020.06.009.; Kent B.D., d'Ancona G., Fernandes M. et al. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020; 6 (1): 003112019. DOI:10.1183/23120541.00311-2019.; Nanzer A.M., Dhariwal J., Kavanagh J. et al. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020; 6 (4): 00451-2020. DOI:10.1183/23120541.00451-2020.; Guntur V.P., Manka L.A., Denson J.L. et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. Pract. 2021; 9 (3): 1186-1193. e1. DOI:10.1016/j.jaip.2020.09.054.; Manka L.A., Guntur V.P., Denson J.L. et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann. Allergy Asthma Immunol. 2021; 126 (6): 696-701.e1. DOI:10.1016/j.anai.2021.01.035.; Mohammad A.J., Hot A., Arndt F. et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann. Rheum. Dis. 2016; 75 (2): 396-401. DOI:10.1136/annrheum-dis-2014-206095.; Roccatello D., Baldovino S., Alpa M. et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin. Exp. Rheumatol. 2008; 26 (3, Suppl. 49): S67-71. Available at: https://pubmed.ncbi.nlm.nih.gov/18799057/; Seeliger B., Forster M., Happe J. et al. Interferon-a for induction and maintenance of remission in eosinophilic granulomatosis with polyangiitis: a single-center retrospective observational cohort study. J. Rheumatol. 2017; 44 (6): 806-814. DOI:10.3899/jrheum.160907.; Lyons P., Peters J., Alberici F. et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat. Commun. 2019; 10 (1): 5120. DOI:10.1038/s41467-019-12515-9.; Mukhtyar C., Flossmann O., Hellmich B. et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 2008; 67 (7): 1004-1010. DOI:10.1136/ard.2007.071936.; Mahr A., Moosig F., Neumann T. et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etio-pathogenesis, assessment and management. Curr. Opin. Rheumatol. 2014; 26 (1): 16-23. DOI:10.1097/BOR.0000000000000015.; Gayraud M., Guillevin L., le Toumelin P. et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001; 44 (3): 666-675. DOI:10.1002/1529-0131(200103)44:33.0.CO;2-A.; Exley A.R., Bacon P.A., Luqmani R.A. et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br. J. Rheumatol. 1998; 37 (1): 57-63. DOI:10.1093/rheumatology/37.1.57.; Arbach O., Metzler C., Gause A. [Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients]. Z. Rheumatol. 2004; 63 (4): 339-340. DOI:10.1007/s00393-004-0538-y (in German).; https://journal.pulmonology.ru/pulm/article/view/4118